MX358019B - Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos. - Google Patents

Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.

Info

Publication number
MX358019B
MX358019B MX2014014024A MX2014014024A MX358019B MX 358019 B MX358019 B MX 358019B MX 2014014024 A MX2014014024 A MX 2014014024A MX 2014014024 A MX2014014024 A MX 2014014024A MX 358019 B MX358019 B MX 358019B
Authority
MX
Mexico
Prior art keywords
sadv
subfamily
simian adenoviruses
simian adenovirus
sequences
Prior art date
Application number
MX2014014024A
Other languages
English (en)
Other versions
MX2014014024A (es
Inventor
James M Wilson
Soumitra Roy
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2014014024A publication Critical patent/MX2014014024A/es
Publication of MX358019B publication Critical patent/MX358019B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a vectores recombinantes comprenden secuencias de adenovirus de simio A1302 (SAdV-A1302, SAdV-A1320, SAdV-A1331 y/o SAdV-A1337, y un gen heterólogo bajo el control de secuencias reguladoras; también se describe una línea celular que expresa gen(es) de adenovirus de simio SAdVA1302, SAdV-A1320, SAdV-A1331 y/o SAdV-A1337; se proporcionan métodos del uso de los vectores y líneas celulares.
MX2014014024A 2012-05-18 2013-05-17 Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos. MX358019B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649007P 2012-05-18 2012-05-18
US201361784142P 2013-03-14 2013-03-14
PCT/US2013/041565 WO2013173702A2 (en) 2012-05-18 2013-05-17 Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof

Publications (2)

Publication Number Publication Date
MX2014014024A MX2014014024A (es) 2015-02-10
MX358019B true MX358019B (es) 2018-08-02

Family

ID=49584464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014024A MX358019B (es) 2012-05-18 2013-05-17 Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.

Country Status (11)

Country Link
US (2) US9217159B2 (es)
EP (1) EP2850194A4 (es)
JP (1) JP6293738B2 (es)
KR (1) KR20150014505A (es)
CN (1) CN105473723A (es)
AU (1) AU2013262626B2 (es)
BR (1) BR112014028684A2 (es)
CA (1) CA2873509A1 (es)
MX (1) MX358019B (es)
SG (2) SG10201609511XA (es)
WO (1) WO2013173702A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016057387A1 (en) 2014-10-06 2016-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for isolation of circulating tumor cells (ctc)
US10335466B2 (en) 2014-11-05 2019-07-02 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of parkinson's disease
JP2017535266A (ja) 2014-11-14 2017-11-30 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）を治療する組成物および方法
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
JP7220080B2 (ja) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド ハンチントン病治療組成物及び方法
SG11201900808SA (en) 2016-08-01 2019-02-27 Wistar Inst Compositions and methods of replication deficient adenoviral vectors for vaccine applications
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
AU2018261003A1 (en) 2017-05-05 2019-11-14 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's Disease
TW202333779A (zh) 2017-05-08 2023-09-01 美商磨石生物公司 阿爾法病毒新抗原載體
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP4124658A3 (en) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP7438943B2 (ja) * 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
SG11202003290RA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
SG11202003398SA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus vectors and uses thereof
KR20200077559A (ko) 2017-10-31 2020-06-30 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
SG11202006400UA (en) 2018-01-04 2020-08-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
EP3807404A1 (en) 2018-06-13 2021-04-21 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
WO2020072844A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
JP2022505106A (ja) 2018-10-15 2022-01-14 ボイジャー セラピューティクス インコーポレイテッド バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
CN110437317B (zh) * 2019-01-30 2023-05-02 上海科技大学 具有变异衣壳蛋白的腺相关病毒及其用途
KR20210130158A (ko) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1364343A1 (ru) 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получени человеческого лейкоцитарного интерферона альфа-2
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
EP0804076A4 (en) 1994-10-19 1998-10-21 Genetic Therapy Inc GENTHERAPY THROUGH SIMULTANEOUS AND REPEATED ADMINISTRATION OF ADENOVIRUS AND IMMUNE SUPPRESSIVES
AU704391B2 (en) 1994-10-28 1999-04-22 Trustees Of The University Of Pennsylvania, The Improved adenovirus and methods of use thereof
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU1822499A (en) 1997-12-12 1999-06-28 Saint Louis University Ctip, a novel protein that interacts with ctbp and uses therefor
CA2317941A1 (en) 1998-01-16 1999-07-22 Genzyme Corporation Adenoviral vectors with modified capsid proteins
ES2235470T3 (es) 1998-03-20 2005-07-01 The Trustees Of The University Of Pennsylvania Composiciones y metodos para la produccion libre de cooperadores de virus adnoasociados recombinantes.
US6210663B1 (en) 1998-08-20 2001-04-03 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
JP2002523105A (ja) 1998-08-27 2002-07-30 アバンテイス・フアルマ・エス・アー 異種遺伝子の運搬用の標的化アデノウイルスベクター
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
AP2002002592A0 (en) 2000-01-31 2002-09-30 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
WO2001058940A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
CA2852277C (en) 2001-11-21 2018-02-20 Guangping Gao Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
ES2478625T3 (es) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
FR2860004A1 (fr) 2003-09-18 2005-03-25 Roussy Inst Gustave Nouveau vecteur adenoviral pour l'infection de cellules deficientes ou depourvues en recepteurs car
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20080004236A1 (en) 2004-02-06 2008-01-03 Comper Wayne D High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
US7741099B2 (en) * 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
AU2005293572B2 (en) 2004-10-14 2011-08-04 Crucell Holland B.V. Malaria prime/boost vaccines
CA2597754A1 (en) 2005-02-12 2006-08-17 Viranative Ab Methods and uses of antibodies in the purification of interferon
CN101384722A (zh) 2005-05-12 2009-03-11 葛兰素集团有限公司 疫苗组合物
EP1893636A2 (en) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
ES2341501T3 (es) 2006-04-28 2010-06-21 The Trustees Of The University Of Pennsylvania Proteina hexon de adenovirus modificado y usos de la misma.
CN101883857B (zh) 2007-11-28 2015-08-12 宾夕法尼亚大学托管会 猿猴亚家族B腺病毒SAdV-28、-27、-29、-32、-33和-35及其应用
AU2008350937B2 (en) 2007-11-28 2014-10-09 The Trustees Of The University Of Pennsylvania Simian subfamily C adenovirus SAdV-31 and uses thereof
HUE032142T2 (en) 2007-11-28 2017-08-28 Univ Pennsylvania Simian E Adenovirus Adenovirus addovirus containing the SAdV-39 capsid hexon protein and its applications
WO2009136977A2 (en) 2008-03-04 2009-11-12 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
WO2010051367A1 (en) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
SG172935A1 (en) * 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
EP2777185B1 (en) 2011-10-13 2016-08-24 Telefonaktiebolaget LM Ericsson (publ) Method and node related to channel estimation

Also Published As

Publication number Publication date
JP6293738B2 (ja) 2018-03-14
CA2873509A1 (en) 2013-11-21
US10113182B2 (en) 2018-10-30
EP2850194A4 (en) 2016-06-08
WO2013173702A9 (en) 2015-05-28
AU2013262626A1 (en) 2014-12-04
WO2013173702A3 (en) 2014-03-13
JP2015519058A (ja) 2015-07-09
AU2013262626B2 (en) 2018-11-29
EP2850194A2 (en) 2015-03-25
US9217159B2 (en) 2015-12-22
WO2013173702A2 (en) 2013-11-21
BR112014028684A2 (pt) 2017-07-25
MX2014014024A (es) 2015-02-10
US20130315871A1 (en) 2013-11-28
CN105473723A (zh) 2016-04-06
US20160083749A1 (en) 2016-03-24
SG10201609511XA (en) 2016-12-29
KR20150014505A (ko) 2015-02-06
SG11201407343XA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
MX2014014024A (es) Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
WO2012071318A3 (en) Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
MX2010005860A (es) Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos.
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
MX2010005858A (es) Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
EP3137120A4 (en) In vivo gene engineering with adenoviral vectors
WO2009136977A3 (en) Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
AU2015317711B2 (en) Compositions comprising recombinant Bacillus cells and another biological control agent
MX2018001215A (es) Adenovirus novedoso.
IN2014DN08812A (es)
EP4279588A3 (en) Engineering of systems, methods and optimized guide compositions for sequence manipulation
EP3436576A4 (en) CELL LINE FOR THE PRODUCTION OF RECOMBINANT PROTEIN AND / OR A RECOMBINANT VIRAL VECTOR
IN2014DN03061A (es)
EP4223317A3 (en) Modulation of complement activity
IN2014DN03005A (es)
MX2013003169A (es) Preimpregnados con base en una composicion de poliuretano reactiva o altamente reactiva estable al almacenamiento.
EP3271685A4 (en) Characterization of refractory lining of metallurgical vessels using autonomous scanners
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
WO2013052832A3 (en) Simian (gorilla) adenovirus or adenoviral vectors and methods of use
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
EP3998341A3 (en) Adenoviral vectors
PH12018500155A1 (en) Recombinant orf virus vector
IN2014MN00246A (es)
WO2011084647A3 (en) Toxin-immunity system
WO2018060368A3 (en) COMPOSITIONS AND METHODS FOR ENHANCING STABILITY OF TRANSGENES IN POXVIRUSES

Legal Events

Date Code Title Description
FG Grant or registration